(S (NP-TMP (NP (NN Building)) (PP (PP (IN on) (NP (NP (NNP Yu) (CC and) (NNP Kumbier) (POS 's)) (NN PCS) (NN framework))) (CC and) (PP (IN for) (NP (JJ randomized) (NNS experiments))))) (, ,) (NP (PRP we)) (VP (VBP introduce) (NP (NP (DT a) (JJ novel) (NN methodology)) (PP (IN for) (NP (JJ Stable) (NNP Discovery))) (PP (IN of) (NP (NP (JJ Interpretable) (NNS Subgroups)) (PP (IN via) (NP (NN Calibration) (-LRB- -LRB-) (NN StaDISC) (-RRB- -RRB-)))))) (, ,) (PP (IN with) (NP (JJ large) (JJ heterogeneous) (NN treatment) (NNS effects)))) (. .))
(S (S (NP (NN StaDISC)) (VP (VBD was) (VP (VBN developed) (PP (IN during) (NP (NP (PRP$ our) (NN re-analysis)) (PP (IN of) (NP (DT the) (NML (CD 1999) (SYM -) (CD 2000)) (NN VIGOR) (NN study)))))))) (, ,) (NP (DT an) (CD 8076) (NN patient)) (VP (VBD randomized) (NP (NP (VBN controlled) (NN trial)) (, ,) (SBAR (IN that) (S (VP (VBN compared) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (PP (IN from) (NP (NP (DT a) (ADJP (RB then) (RB newly) (VBN approved)) (NN drug)) (, ,) (NP (NNP Rofecoxib))))))) (PRN (-LRB- -LRB-) (NP (NNP Vioxx)) (-RRB- -RRB-))))) (, ,)) (PP (IN to) (NP (NP (DT that)) (PP (IN from) (NP (DT an) (NML (JJR older) (NN drug)) (NNP Naproxen)))))) (. .))
(S (NP (NNP Vioxx)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VP (, ,) (PP (PP (IN on) (ADJP (JJ average))) (CC and) (PP (IN in) (NP (NP (NN comparison)) (PP (IN to) (NP (NNP Naproxen)))))) (, ,) (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ gastrointestinal) (-LRB- -LRB-) (NN GI) (-RRB- -RRB-) (NNS events))))) (CC but) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ thrombotic) (JJ cardiovascular) (-LRB- -LRB-) (NN TC) (-RRB- -RRB-) (NNS events)))))))))) (. .))
(S (S (VP (VBG Applying) (NP (NN StaDISC)))) (, ,) (NP (PRP we)) (VP (VP (VBP fit) (NP (NP (CD 18) (JJ popular) (NML (NML (JJ conditional) (JJ average) (NN treatment)) (NN effect) (-LRB- -LRB-) (NML (NN CATE)) (-RRB- -RRB-)) (NNS estimators)) (PP (IN for) (NP (DT both) (NNS outcomes))))) (CC and) (VP (VB use) (NP (NN calibration)) (S (VP (TO to) (VP (VB demonstrate) (NP (PRP$ their) (JJ poor) (JJ global) (NN performance))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (PRP they)) (VP (VBP are) (ADJP (ADJP (RB locally) (RB well) (HYPH -) (VBN calibrated)) (CC and) (ADJP (JJ stable))) (, ,) (S (VP (VBG enabling) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (JJ patient) (NNS groups)))) (PP (IN with) (NP (NP (JJR larger)) (PP (IN than) (PRN (-LRB- -LRB-) (VP (VBN estimated)) (-RRB- -RRB-)) (NP (JJ average) (NN treatment) (NNS effects)))))))) (. .))
(S (PP (IN In) (NP (NN fact))) (, ,) (NP (NNP StaDISC)) (VP (VBZ discovers) (NP (CD three) (ADJP (RB clinically) (JJ interpretable)) (NNS subgroups)) (PP (IN for) (NP (NP (NP (DT the) (NN GI) (NN outcome)) (-LRB- -LRB-) (VP (VBG totaling) (NP (NP (CD 29.4) (NN %)) (PP (IN of) (NP (DT the) (NN study) (NN size))))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NP (CD two)) (-LRB- -LRB-) (VP (VBG totaling) (NP (CD 5.6) (NN %))) (-RRB- -RRB-)) (PP (IN for) (NP (DT the) (NN TC) (NN outcome))))))) (. .))
(S (PP (IN Amongst) (NP (PRP them))) (, ,) (NP (NP (DT the) (NN subgroup)) (PP (IN of) (NP (NP (NNS people)) (PP (IN with) (NP (NP (DT a) (JJ prior) (NN history)) (PP (IN of) (NP (NN GI) (NNS events) (PRN (-LRB- -LRB-) (NP (NP (CD 7.8) (NN %)) (PP (IN of) (NP (DT the) (NN study) (NN size)))) (-RRB- -RRB-))))))))) (VP (CONJP (RB not) (RB only)) (VP (VBZ has) (NP (NP (DT a) (ADJP (ADVP (RB disproportionately)) (VBN reduced)) (NN risk)) (PP (IN of) (NP (NN GI) (NNS events))))) (CC but) (ADVP (RB also)) (VP (VBZ does) (RB not) (VP (VB experience) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN TC) (NNS events))))))) (. .))
